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Blood transfusions have become indispensable to treat the anemia associated with 
a variety of medical conditions ranging from genetic disorders and cancer to exten-
sive surgical procedures. In developed countries, the blood supply is generally ade-
quate. However, the projected decline in blood donor availability due to population 
ageing and the difficulty in finding rare blood types for alloimmunized patients indi-
cate a need for alternative red blood cell (RBC) transfusion products.
Increasing knowledge of processes that govern erythropoiesis has been translat-
ed into efficient procedures to produce cultured RBC (cRBC) using primary hemat-
opoietic stem cells, embryonic stem cells, or induced pluripotent stem cells. In addi-
tion, proof-of-principle studies in lethally bled animal models suggest that these 
cRBC may represent alternative transfusion products. Compared to other cell thera-
pies, however, transfusion poses the unique challenge of requiring great cell doses 
(2.5×1012 vs 107 cells). Although production of such cell numbers is theoretically pos-
sible, current technologies generate cRBC in numbers sufficient only for quality con-
trol and safety studies. Since cRBCs have entered clinical evaluation, several issues 
related to their production are under intense scrutiny. Examples of issues that will 
be addressed in the future are the identification of stem cell sources more suitable 
for cRBC generation, the translation of cRBC culture methods into clinical grade pro-
duction processes, and the development of protocols to achieve optimal cRBC qual-
ity, quantity, and maturation. We will discuss data on size, hemoglobin, blood group 
antigen expression and phosphoproteomic profiling obtained on cRBCs expanded ex 
vivo from a limited number of regular blood donors, including a donor with a rare 
blood phenotype, as examples of the type of measurements that are being generated 
as part of the quality control assessment of the suitability of cRBCs for transfusion. 
It is conceived that by the time all these quality studies will be completed, technical 
barriers to mass cell production will have been eliminated making transfusion with 
cRBCs a reality. 
